Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis: a Phase IIB Study
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 06 Apr 2015 Planned number of patients changed from 40 to 41 as reported by ClinicalTrials.gov record.
- 06 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 08 Mar 2014 New trial record